巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Onconova Therapeutics

    ONTX
    1.090
    0.030
    2.68%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Onconova Therapeutics - 延遲價格・最後更新於 20/05 12:15
    最高位
    1.090
    最低位
    1.060
    開市價
    --
    前收市價
    1.120
    成交量(千)
    0.21
    成交額(百萬)
    0.00
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    22.78
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    10.840 - 1.000
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Onconova Therapeutics
    證券代碼
    ONTX.US
    所屬板塊
    Biotechnology
    公司業務
    Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.
    發行量
    20895563
    公司總部
    12 Penns Trail
    公司網址
    https://www.onconova.com
    公司電郵
    ir@onconova.us
    公司電話
    +1 267 759-3680
    暫無內容

    關於

    Onconova Therapeutics(ONTX.US)所屬的行業板塊為Biotechnology。
    Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.
    詳細公司背景可參考: https://www.onconova.com